Medtronic(US:MDT) 智通财经网·2025-08-19 12:20Group 1 - Medtronic reported Q1 FY2026 revenue of $8.6 billion, exceeding market expectations of $8.4 billion, driven by growth in the cardiovascular products segment, with cardiac ablation product revenue increasing nearly 50% [1] - Adjusted EPS grew by 2% to $1.26, surpassing the market forecast of $1.23 [1] - Medtronic lowered its tariff cost forecast to $185 million from a previous estimate of $200 million to $350 million [1] Group 2 - Medtronic raised its FY2026 adjusted EPS guidance to a range of $5.60 to $5.66, up from the prior forecast of $5.50 to $5.60 [1] - The company continues to expect an organic revenue growth rate of 5% for FY2026 [1] - Following the investment from Elliott Investment Management, Medtronic plans to expand its board and appoint experienced individuals in the medical technology field as independent directors [2]